AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02435069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Response - NS and USP Glycerin - First Intervention
Description: This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
Study NCT02435069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effectiveness - NS and USP Glycerin - Second Intervention
Description: To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
Study NCT03979430 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home spirometry
Description: Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
Study NCT00843726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1 stereotactic body radiation therapy
Description: Patients undergo 1 high-dose fraction
Study NCT00843726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm II stereotactic body radiation therapy
Description: Patients undergo 3 high-dose fractions
Study NCT00800748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
Study NCT00800748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
Study NCT00072176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00072176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00900198 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
Study NCT04349436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1, intra-tumoral injection, oncolytic virus
Description: Genetically modified herpes simplex type 1 virus
Study NCT03475693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: 400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
Study NCT03475693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
Study NCT03475693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
Study NCT03475693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran ODT 4 MG Disintegrating Oral Tablet
Description: Given once in the Emergency department
Study NCT03475693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT 4 MG Disintegrating Oral Tablet
Description: Given once in the Emergency department
Study NCT03592693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Vitamin C and Stress-Dose Hydrocortisone
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Study NCT03592693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus placebo
Description: Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
Study NCT05267873 — intervention group
Intervention type: DRUG
Intervention: Duloxetine, Vortioxetine
Description: Medications for major depressive disorder
Study NCT04048200 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
Study NCT04048200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Ketamine
Description: No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
Study NCT01350518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Benefiber
Description: Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten.
Study NCT01350518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TrueLemon
Description: Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
Study NCT04210323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker®
Description: The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
Study NCT04210323 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
Study NCT04457219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haemostatic Dressing
Description: A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
Study NCT04457219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing
Description: A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
Study NCT04457219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Dressing
Description: A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
Study NCT04457219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 120 Minutes External Compression
Description: A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
Study NCT04457219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 60 Minutes External Compression
Description: A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
Study NCT02906371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
Study NCT02906371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
Study NCT02906371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CART 19
Description: CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
Study NCT03903653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)
Study NCT03903653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)
Study NCT03377114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral
Description: When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
Study NCT03377114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head tilting
Description: When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
Study NCT05876936 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: contact lens sensor (CLS) SENSIMED Triggerfish®
Description: contact lens sensor CLS placing and fitting evaluation, 24h recording
Study NCT03434743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative
Description: Non-nutritive sucking on emptied breast
Study NCT02699762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self rehabilitation of upper limb in experimental group
Description: The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
Study NCT00273013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: GW274150 will be available as 30 mg white oval tablets.
Study NCT04509648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam radiotherapy using IMRT technique
Description: 2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
Study NCT04073225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindPod Dolphin
Description: The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience.
Study NCT04073225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Bike
Description: The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
Study NCT02802969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete.
Study NCT02802969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protontherapy
Description: Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
Study NCT02802969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FAZA
Description: FAZA PET/CT, in order to target the hypoxic zones
Study NCT03765879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)
Description: In VGAIT treatment sessions, participants will re-watch the video of an avatar receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
Study NCT03765879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)
Description: In sham VGAIT treatment sessions, participants will re-watch this video of an avatar receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
Study NCT02829437 — intervention group
Intervention type: OTHER
Intervention: Treatment for EST
Description: Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
Study NCT04436640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at prespecified time-points.
Study NCT03143322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be added to systemic (standard) treatment of bone metastases.
Study NCT03528694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Investigational product
Study NCT03528694 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Standard of care
Study NCT03528694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Standard of care
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
Study NCT04351555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
Study NCT05309590 — intervention group
Intervention type: DRUG
Intervention: Dose
Description: The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
Study NCT01645722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure/Surgery: Enriched Fat grafting
Description: Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
Study NCT02912988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
Study NCT01327911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-501 implant
Description: Ciliary neurotrophic factor (CNTF) implant
Study NCT02208700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxepa
Description: Therapeutic nutrition with EPA, GLA\< and antioxidants
Study NCT02208700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jevity 1.5
Description: Complete balanced nutrition with a unique fiber blend
Study NCT04446442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
Study NCT04446442 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
Study NCT03434743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Non-nutritive sucking on pacifier
Study NCT02445391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT02445391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02445391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03955380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any exipients.
Study NCT03955380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any exipients.